Phenobarbital induces the 2-hydroxylation of desipramine

The kinetics of a single oral dose of desipramine (DMI; 100 mg) were studied in eight epileptic patients chronically treated with phenobarbital (PB) and in eight drug-free healthy controls. All subjects were extensive metabolizers with respect to the genetically determined CYP2D6-related metabolic polymorphism. Compared with controls, epileptic patients exhibited lower peak plasma DMI concentrations (74 ± 24 vs. 107 ± 32 nmol/L; means ± SD, p < 0.05), smaller DMI area-under-the-curve values (1,943 ± 461 vs. 3,234 ± 1,145 nmol L h; p < 0.01), and shorter DMI elimination half- lives (15.1 ± 2.1 vs. 20.6 ± 3.4 h; p < 0.01). The proportion of the dose excreted as 2-hydroxydesipramine (2-OH-DMI) was significantly higher in the patients (54 ± 8 vs. 40 ± 9%; p < 0.05). In one single poor metabolizer volunteer, a 3-week treatment with PB was associated with no major changes in DMI kinetics, but the urinary excretion of 2-OH-DMI tended to increase. These results suggest that PB is an inducer of the 2-hydroxylation of DMI, a reaction primarily catalyzed by CYP2D6, but do not provide further information on the specific P450 isoenzyme(s) being induced.